# Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen

> **NCT07061379** · — · RECRUITING · sponsor: **IRCCS San Raffaele** · enrollment: 144 (estimated)

## Conditions studied

- PROMs

## Interventions

- **DRUG:** Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity
- **DRUG:** Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity

## Key facts

- **NCT ID:** NCT07061379
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2027-06
- **Final completion:** 2031-06
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-09-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07061379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07061379, "Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07061379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*